Immune protection is dependent on the gut microbiome in a lethal mouse gammaherpesviral infection
Yaron, Jordan R.; Ambadapadi, Sriram; Zhang, Liqiang; Chavan, Ramani N.; Tibbetts, Scott A.; Keinan, Shahar; Varsani, Arvind; Maldonado, Juan; Kraberger, Simona; Tafoya, Amanda M.; Bullard, Whitney L.; Kilbourne, Jacquelyn; Stern-Harbutte, Alison; Krajmalnik-Brown, Rosa; Munk, Barbara H.; Koppang, Erling Olaf; Lim, Efrem S.; Lucas, Alexandra R.
Peer reviewed, Journal article
Published version
View/ Open
Date
2020Metadata
Show full item recordCollections
Abstract
Immunopathogenesis in systemic viral infections can induce a septic state with leaky capillary syndrome, disseminated coagulopathy, and high mortality with limited treatment options. Murine gammaherpesvirus-68 (MHV-68) intraperitoneal infection is a gammaherpesvirus model for producing severe vasculitis, colitis and lethal hemorrhagic pneumonia in interferon gamma receptor-deficient (IFNγR−/−) mice. In prior work, treatment with myxomavirus-derived Serp-1 or a derivative peptide S-7 (G305TTASSDTAITLIPR319) induced immune protection, reduced disease severity and improved survival after MHV-68 infection. Here, we investigate the gut bacterial microbiome in MHV-68 infection. Antibiotic suppression markedly accelerated MHV-68 pathology causing pulmonary consolidation and hemorrhage, increased mortality and specific modification of gut microbiota. Serp-1 and S-7 reduced pulmonary pathology and detectable MHV-68 with increased CD3 and CD8 cells. Treatment efficacy was lost after antibiotic treatments with associated specific changes in the gut bacterial microbiota. In summary, transkingdom host-virus-microbiome interactions in gammaherpesvirus infection influences gammaherpesviral infection severity and reduces immune modulating therapeutic efficacy.